Table 2.

IC50 in NA inhibition assays at baseline for the intent-to-treat infected populationa

Influenza virus subtype (n) and treatment groupIC50 (nM)
Mean ± SDMedian (range)b
A/H1 (593)
    Peramivir22.25 ± 4.3721.59 (0.41–100.00)
    Oseltamivir87.70 ± 16.38100.00 (0.66–100.00)
    Zanamivir1.35 ± 0.181.34 (0.97–3.41)
A/H3 (323)
    Peramivir0.83 ± 0.170.82 (0.45–2.13)
    Oseltamivir0.63 ± 0.170.62 (0.27–1.84)
    Zanamivir1.97 ± 0.371.91 (1.46–5.93)
B (70)
    Peramivir3.51 ± 0.393.58 (2.18–4.33)
    Oseltamivir16.53 ± 2.3016.77 (8.77–22.33)
    Zanamivir9.74 ± 1.109.79 (5.92–12.17)
  • a The reliability of each assay was confirmed by the observation that the IC50 of peramivir ranged from 0.2 to 2 nM for the standard strain (A/PR/8/34).

  • b Minimum to maximum IC50. The upper limit of the IC50 was 100.0 nM.